Avidity Biosciences, Inc. (RNAM)
NASDAQ: RNAM · Real-Time Price · USD
72.82
+0.02 (0.03%)
At close: Feb 26, 2026
Avidity Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 382.52 | 219.87 | 185.08 | 340.4 | 320.45 |
Short-Term Investments | 1,314 | 1,282 | 410.27 | 270.33 | 85.1 |
Cash & Short-Term Investments | 1,697 | 1,501 | 595.35 | 610.73 | 405.54 |
Cash Growth | 13.01% | 152.20% | -2.52% | 50.59% | 23.59% |
Accounts Receivable | - | - | 1.11 | 2.36 | 0.9 |
Other Receivables | 12.44 | 9.45 | 7.52 | 1.51 | - |
Receivables | 12.44 | 9.45 | 8.62 | 3.88 | 0.9 |
Prepaid Expenses | 36.46 | 12.57 | 7.33 | 8.34 | 4.7 |
Other Current Assets | 52.7 | 18.78 | - | - | - |
Total Current Assets | 1,798 | 1,542 | 611.31 | 622.94 | 411.14 |
Property, Plant & Equipment | 74.61 | 18.29 | 16.65 | 15.01 | 15.59 |
Other Long-Term Assets | 84.97 | 3.32 | 0.6 | 0.85 | 0.85 |
Total Assets | 1,958 | 1,564 | 628.56 | 638.8 | 427.58 |
Accounts Payable | 12.4 | 8.46 | 8.81 | 4.64 | 2.81 |
Accrued Expenses | 157.47 | 64.73 | 39.87 | 39.13 | 20.22 |
Current Portion of Leases | 3.94 | 3.84 | 3.64 | 3.11 | 1.77 |
Current Unearned Revenue | 21.64 | 20.99 | 28.37 | 5.04 | 4.86 |
Total Current Liabilities | 195.45 | 98.02 | 80.68 | 51.91 | 29.66 |
Long-Term Leases | 45.31 | 2.96 | 6.21 | 7.58 | 9.96 |
Long-Term Unearned Revenue | 28.69 | 37.96 | 40.9 | 1.24 | 6.53 |
Total Liabilities | 269.45 | 138.94 | 127.79 | 60.73 | 46.15 |
Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 3,264 | 2,315 | 1,071 | 939.31 | 566.16 |
Retained Earnings | -1,578 | -893.07 | -570.76 | -358.54 | -184.55 |
Comprehensive Income & Other | 2.56 | 2.9 | 0.13 | -2.7 | -0.19 |
Total Common Equity | 1,689 | 1,425 | 500.76 | 578.08 | 381.43 |
Shareholders' Equity | 1,689 | 1,425 | 500.76 | 578.08 | 381.43 |
Total Liabilities & Equity | 1,958 | 1,564 | 628.56 | 638.8 | 427.58 |
Total Debt | 49.25 | 6.8 | 9.85 | 10.69 | 11.73 |
Net Cash (Debt) | 1,648 | 1,495 | 585.5 | 600.04 | 393.81 |
Net Cash Growth | 10.23% | 155.29% | -2.42% | 52.37% | 20.36% |
Net Cash Per Share | 11.96 | 13.40 | 8.02 | 11.50 | 9.51 |
Filing Date Shares Outstanding | 155.15 | 120.21 | 79.72 | 70.81 | 47.75 |
Total Common Shares Outstanding | 151.21 | 119.89 | 79.28 | 69.77 | 47.75 |
Working Capital | 1,603 | 1,444 | 530.63 | 571.03 | 381.48 |
Book Value Per Share | 11.17 | 11.89 | 6.32 | 8.29 | 7.99 |
Tangible Book Value | 1,689 | 1,425 | 500.76 | 578.08 | 381.43 |
Tangible Book Value Per Share | 11.17 | 11.89 | 6.32 | 8.29 | 7.99 |
Machinery | 32.31 | 16.42 | 13.31 | 9.13 | 6.29 |
Construction In Progress | 0.1 | 3.96 | - | - | - |
Leasehold Improvements | 2.71 | 0.29 | 0.29 | 0.25 | 0.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.